Get the Stockscreener App
5.67
14.26%
-0.92
After Hours:
5.61
-0.06
-1.06%
Alumis Inc stock is traded at $5.67, with a volume of 1.47M.
It is down -14.26% in the last 24 hours and down -29.81% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$6.59
Open:
$5.33
24h Volume:
1.47M
Relative Volume:
9.23
Market Cap:
$308.49M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.2115
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-24.47%
1M Performance:
-29.81%
6M Performance:
-53.54%
1Y Performance:
+0.00%
1-Day Range:
$4.855
$6.20
1-Week Range:
$4.855
$7.63
52-Week Range:
$4.855
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
5.67 | 308.49M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Alumis Inc (NASDAQ:ALMS) stock crossing the finish line today - US Post News
Alumis and Acelyrin sign agreement to merge - Pharmaceutical Technology
H.C. Wainwright cuts Alumis stock target to $19, maintains Buy rating - Investing.com India
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases - BioSpace
Leerink Partnrs Forecasts Alumis FY2029 Earnings - MarketBeat
Immune drugmakers Alumis and Acelyrin to merge - BioPharma Dive
Alumis and ACELYRIN announce all-stock merger to focus on immune diseases - World Pharmaceutical Frontiers
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Alumis stock falls on merger deal with Acelyrin (SLRN:NASDAQ) - Seeking Alpha
We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate - Yahoo Finance UK
Acelyrin to be absorbed into Alumis in all-stock merger - Fierce Biotech
Alumis and Acelyrin merge, with $737 million cash runway - The Pharma Letter
Alumis and ACELYRIN announce merger in all-stock deal By Investing.com - Investing.com Nigeria
Alumis (ALMS) Projected to Post Earnings on Wednesday - MarketBeat
Struggling immunology firms Alumis and Acelyrin to merge - FirstWord Pharma
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders - The Bakersfield Californian
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders - Business Wire
Less than two years after blockbuster IPO, Acelyrin merges with Alumis to combine cash, assets - Endpoints News
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company -February 06, 2025 at 05:56 pm EST - Marketscreener.com
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders - Business Wire
Alumis and ACELYRIN announce merger in all-stock deal - Investing.com India
Alumis, Acelyrin to merge in all-stock transaction - TipRanks
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
Fenwick Represents ACELYRIN in Pending Merger with Alumis - Fenwick & West LLP
Alumis (ALMS) Expected to Announce Earnings on Wednesday - Defense World
Alumis (NASDAQ:ALMS) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
JPMorgan Chase & Co. Takes $191,000 Position in Alumis Inc. (NASDAQ:ALMS) - Defense World
Oppenheimer Begins Coverage on Alumis (NASDAQ:ALMS) - Defense World
Why Alumis (ALMS) Stock Is Advancing Today - MSN
Oppenheimer sets Alumis stock with Outperform, $32 target By Investing.com - Investing.com Canada
Alumis draws Outperform at Oppenheimer on valuation disconnect (ALMS:NASDAQ) - Seeking Alpha
Oppenheimer sets Alumis stock with Outperform, $32 target - MSN
Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target - Marketscreener.com
Wyman joins Scholar Rock - BioCentury
Alumis Inc. bolsters leadership for late-stage development By Investing.com - Investing.com South Africa
Biotech Company Alumis Names Sara Klein Chief Legal Officer - Bloomberg Law
Alumis Inc. bolsters leadership for late-stage development - Investing.com
Alumis Strengthens Leadership Team with Key Appointments - The Manila Times
Former Amgen Star Who Drove $4B Revenue Growth Joins Alumis to Lead Blockbuster Drug Launch - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of “Buy” by Brokerages - Defense World
JMP Securities Reaffirms Market Perform Rating for AFC Gamma (NASDAQ:AFCG) - Defense World
TechTarget (NASDAQ:TTGT) Now Covered by Analysts at StockNews.com - Defense World
Zovio (NYSE:ZVO) Coverage Initiated at StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Landmark Bancorp (NASDAQ:LARK) Now Covered by StockNews.com - Defense World
Alumis Inc. (NASDAQ:ALMS) Receives $26.83 Average Target Price from Brokerages - MarketBeat
Meta Platforms (NASDAQ:META) Shares Up 1.1% on Analyst Upgrade - Defense World
The Hain Celestial Group, Inc. (NASDAQ:HAIN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Capital Management V, | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Tananbaum James B. | Director |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):